T Cell Antigen Receptor Vaccines for Active Therapy of T Cell Malignancies
- 1 September 2001
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 941 (1) , 97-105
- https://doi.org/10.1111/j.1749-6632.2001.tb03714.x
Abstract
T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoidesKeywords
This publication has 32 references indexed in Scilit:
- Idiotypic DNA Vaccines Against B‐cell LymphomaImmunological Reviews, 1995
- The use of anchored polymerase chain reaction for the study of large numbers of human T-cell receptor transcriptsMolecular Immunology, 1993
- Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked FormScience, 1990
- In vivo T cell tumor therapy with monoclonal antibody directed to the V beta chain of T cell antigen receptor.The Journal of Experimental Medicine, 1989
- Development of a New Therapeutic Approach to B Cell Malignancy. The Induction of Immunity by the Host Against Cell Surface Receptor on the TumorInternational Reviews of Immunology, 1989
- Protection from experimental allergic encephalomyelitis conferred by a monoclonal antibody directed against a shared idiotype on rat T cell receptors specific for myelin basic protein.The Journal of Experimental Medicine, 1988
- Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapyCell, 1988
- Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune interventionCell, 1988
- T-Cell Tumor Elimination as a Result of T-Cell Receptor-Mediated ActivationScience, 1987
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982